A clinical trial of a new gene therapy for sickle cell disease that has shown promise has been halted after two participants were diagnosed with cancer.
Therapy developer Bluebird Bio said a patient who was treated five years ago developed myelodysplastic syndrome, while another developed acute myeloid leukemia, The New York Times reported.
Though it is not yet clear what caused the cancers, one possibility is that the disabled virus used to deliver the gene therapy damaged crucial DNA in blood-forming cells in the patients’ bone marrows. That would be the worst-case scenario, said John Tisdale, M.D., head of the cellular and molecular therapeutics branch at the National Heart, Lung, and Blood Institute.
But there is also the likelihood that both cancers were caused by a powerful drug, busulfan, which is used to clear bone marrow to make space for new cells modified by gene therapy. Busulfan is known to raise blood cancer risk, Tisdale noted.
Muddying the issue even further is the fact that people with sickle cell disease are known to have an increased risk for leukemia, even without treatment. Still, no one would expect two patients in a small trial to get the disease, The Times said.
The New York Times Article
Copyright © 2020 HealthDay. All rights reserved.
Trial of gene therapy for sickle cell disease halted (2021, February 24)
retrieved 24 February 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.